RxSight shareholder sues over alleged product demand misrepresentation.

A shareholder has filed a securities class action lawsuit against RxSight, Inc. for allegedly overstating product demand and failing to disclose declining sales. The lawsuit covers investors who purchased or acquired RxSight securities between November 7, 2024, and July 8, 2025. If you own shares and lost money, you may be eligible to participate in the lawsuit.

A shareholder has filed a securities class action lawsuit against RxSight, Inc. (NASDAQ: RXST) for alleged overstatement of product demand and failure to disclose declining sales. The lawsuit covers investors who purchased or acquired RxSight securities between November 7, 2024, and July 8, 2025. If you own shares and lost money, you may be eligible to participate in the lawsuit.

The lawsuit, filed on August 18, 2025, claims that defendants made false and misleading statements and/or failed to disclose that RxSight was experiencing "adoption challenges" and structural issues resulting in declines in sales and utilization. Additionally, the complaint alleges that the defendants overstated the demand for RxSight's products, which led to the company being unlikely to meet its previously issued financial guidance for fiscal year 2025. As a result, investors suffered damages [2].

Investors who purchased or acquired RxSight securities during the specified period are encouraged to review the details of the lawsuit. If you wish to join the class action, you must file papers by September 22, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery does not require that you serve as lead plaintiff [3].

Levi & Korsinsky, LLP, Bernstein Liebhard LLP, and Rosen Law Firm, among others, are representing the class. Each firm has extensive experience in securities litigation and has secured millions of dollars for investors in the past. The lawsuits are pending in various courts, and investors have until the deadline to join the class action [1][2][3].

For more information and to discuss your legal rights, contact the respective law firms or visit their websites. There is no cost or obligation to participate in the class action, and shareholders pay no fees or expenses [1][2][3].

References:
[1] https://www.morningstar.com/news/globe-newswire/9516489/lost-money-on-rxsight-incrxst-join-class-action-suit-seeking-recovery-contact-levi-korsinsky
[2] https://www.globenewswire.com/news-release/2025/08/18/3134957/0/en/SHAREHOLDER-ALERT-Bernstein-Liebhard-LLP-Announces-A-Securities-Fraud-Class-Action-Lawsuit-Has-Been-Filed-Against-RxSight-Inc-NASDAQ-RXST.html
[3] https://www.marketscreener.com/news/rxst-investors-have-opportunity-to-lead-rxsight-inc-securities-fraud-lawsuit-ce7c50dadb81f427